Updated Monday, 7/20.
One sizable IPO is currently scheduled for the week ahead, though a few notable names are eligible to launch.
Cardiovascular disease biotech Scribe Therapeutics (SCTX) plans to raise $100 million at a $235 million market cap. Scribe is developing in vivo CRISPR-based therapies aimed at extending healthy lifespan through disease prevention, with an initial focus on cardiovascular and metabolic disease. Its lead candidate uses an epigenetic silencing approach to durably lower LDL-C by repressing PCSK9 expression, without permanently altering DNA. It's currently in a first-in-human trial in Australia under TGA clearance, with initial data expected in the first half of 2027.
| U.S. IPO Calendar | |||
|---|---|---|---|
| Issuer Business | Deal Size Market Cap | Price Range Shares Filed | Top Bookrunners |
| Scribe Therapeutics (SCTX) Alameda, CA | $100M $235M | $13 - $15 7,150,000 | Leerink Partners Goldman |
| Phase 1 biotech developing CRISPR genetic therapies for high cholesterol. | |||
Convenience store chain Cumberland Farms (CMBY) its a strong candidate to join the calendar. Consumer IPOs have struggled this year, so this deal will test whether or not there’s any appetite for these stories. Argentine renewables firm Genneia (GENN) could also launch.
Street research will be available for three companies in the week ahead, and two lock-up periods will be expiring. For access to Street research and lock-up expiration dates, sign up for a free trial of IPO Pro.
IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 7/16/2026, the Renaissance IPO Index was up 16.9% year-to-date, while the S&P 500 was up 10.8%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Astera Labs (ALAB) and Reddit (RDDT). The Renaissance International IPO Index was up 39.8% year-to-date, while the ACWX was up 13.4%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Galderma and CATL.
